申请人:Teva Pharmaceutical Industries Limited
公开号:EP0002066A1
公开(公告)日:1979-05-30
The invention provides novel 2-adamantyl hydrazine derivatives of the general formula A
In this formula R, is hydrogen or a lower alkyl group of 1-4 carbon atoms; R2 and R3 are the same or different and are each hydrogen, an unsubstituted or substituted radical being a lower alkyl of 1-4 carbon atoms, a lower alkanoic acid radical of 2-4 carbon atoms or a lower alkyl ester thereof, adamantyl, aryl, aralkyl, in which the alkyl moiety has from 1-4 carbon atoms or an unsubstituted or substituted heterocyclic radical of aromatic character; or R2 and R3 together with the nitrogen atom to which they are attached form an unsubstituted or substituted non-aromatic cyclic radical.
The invention further provides pharmaceutically acceptable acid addition salts of the above compounds.
Several methods of preparation of the new compounds are described.
The novel compounds according to the invention possess valuable antifungal (human and plant), antiviral, antiprotozoal and antimicrobial properties.
本发明提供了通式 A 的新型 2-金刚烷基肼衍生物
在该式中,R为氢或1-4个碳原子的低级烷基;R2和R3相同或不同,各自为氢、未取代或取代的1-4个碳原子的低级烷基、2-4个碳原子的低级烷酸基或其低级烷基酯、金刚烷基、芳基、芳烷基(其中烷基具有1-4个碳原子)或未取代或取代的芳香杂环基;或 R2 和 R3 与它们所连接的氮原子一起形成未取代或取代的非芳香环基。
本发明进一步提供了上述化合物的药学上可接受的酸加成盐。
本发明描述了几种新化合物的制备方法。
本发明的新型化合物具有宝贵的抗真菌(人类和植物)、抗病毒、抗原虫和抗微生物特性。